Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December PR Newswire - Wed Nov 26, 5:30AM CST

NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...

IMUX : 0.5843 (+1.78%)
Immunic: Q3 Earnings Snapshot AP - Thu Nov 13, 5:39AM CST

Immunic: Q3 Earnings Snapshot

IMUX : 0.5843 (+1.78%)
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire - Thu Nov 13, 5:30AM CST

– Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41 st Congress of ECTRIMS  –

IMUX : 0.5843 (+1.78%)
Immunic to Participate in Industry and Investor Conferences in November PR Newswire - Wed Oct 29, 5:30AM CDT

NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies...

IMUX : 0.5843 (+1.78%)
Immunic to Participate in Scientific and Investor Conferences in October PR Newswire - Wed Oct 1, 5:30AM CDT

NEW YORK , Oct. 1, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies...

IMUX : 0.5843 (+1.78%)
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis PR Newswire - Thu Sep 25, 5:30AM CDT

– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over...

IMUX : 0.5843 (+1.78%)
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis PR Newswire - Tue Sep 9, 5:30AM CDT

– Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis –

IMUX : 0.5843 (+1.78%)
Immunic to Participate in Investor and Scientific Conferences in September PR Newswire - Thu Sep 4, 5:30AM CDT

NEW YORK , Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule...

IMUX : 0.5843 (+1.78%)
Immunic: Q2 Earnings Snapshot AP - Thu Aug 7, 5:37AM CDT

Immunic: Q2 Earnings Snapshot

IMUX : 0.5843 (+1.78%)
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire - Thu Aug 7, 5:30AM CDT

– Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Population and Across Subtypes,   ...

IMUX : 0.5843 (+1.78%)

Barchart Exclusives

This Dividend Giant Yielding 4.5% Is Wall Street’s Top Telecom Pick for 2026 Barchart - 24 minutes ago
JPMorgan just released a list of its 47 top stock picks for 2026, but only one comes from the telecom industry, a stock that features an attractive yield and improving cash flow outlook. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot